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Kaposi’s sarcoma-associated herpesvirus (KSHV) is an
important pathogen in Kaposi’s sarcoma and abnormal
lymphoproliferation. KSHV open reading frame 50
(ORF50), a homolog of the Epstein-Barr virus immedi-
ate-early gene product RTA, activates early and late
gene transcription in the KSHV lytic cycle, and its ex-
pression is closely correlated with KSHV-related dis-
eases. ORF50 interacts with the cellular proteins CBP
and histone deacetylase and represses p53-induced apo-
ptosis through a CBP-related mechanism. We show here
that KSHV ORF50 also interacts with STAT3. ORF50
stimulated transcription of STAT-driven reporter genes,
and interleukin-6 and v-Src further activated this stim-
ulating effect of ORF50. Physical association of STAT3
and ORF50 required the carboxyl-terminal transactiva-
tion domain of ORF50 and multiple regions within
STAT3. ORF50 recruited STAT3 to the nucleus and in-
duced the dimerization of STAT3 monomers in the ab-
sence of STAT3 phosphorylation. We show here that
KSHV ORF50 activates STAT3-mediated transcription
through direct interaction without mediating tyrosine
phosphorylation.
Kaposi’s sarcoma-associated herpesvirus (KSHV),1 also
known as human herpesvirus 8, is an important pathogen in
Kaposi’s sarcoma and multicentric Castleman’s disease (1, 2).
In a KSHV infection, the viral DNA is found principally in B
lymphocytes, and KSHV is in fact associated with abnormal
lymphoproliferation such as primary effusion lymphoma (3). In
a Kaposi’s sarcoma tumor, KSHV DNA is found in spindle cells,
and viral lytic replication is important for Kaposi’s sarcoma
tumor development (4). KSHV is a member of the -herpesvi-
rus family and has homology to the other herpesviruses, her-
pesvirus saimiri, and Epstein-Barr virus (EBV).
An important step in the KSHV life is the switch from la-
tency to lytic replication. Upon chemical induction, KSHV pro-
duces RNA transcripts from its immediate-early genes. These
transcripts encode viral transcriptional activator proteins such
as open reading frame 50 (ORF50) and K8, which are necessary
to induce lytic replication (5). ORF50 is a homolog of the EBV
immediate-early gene product RTA. It has been reported that
ORF50 activates the lytic cycle of KSHV and is expressed
earlier than K8, a homolog of the EBV ZTA protein, which
induces the lytic cycle of EBV (6, 7). ORF50 activates expres-
sion of the early and late genes in the KSHV lytic cycle (8).
Demethylation of the ORF50 promoter closely correlates with
expression of the ORF50 gene and induction of the lytic phase
(9). Biopsies from patients with KSHV-related diseases such as
Kaposi’s sarcoma, multicentric Castleman’s disease, and pri-
mary effusion lymphoma show demethylation of the ORF50
promoter, whereas samples from a latently infected KSHV
carrier show a methylated ORF50 promoter. These data sug-
gest that the expression of ORF50 is very important for the
development of KSHV-associated diseases. ORF50 binds to the
cellular proteins CBP and histone deacetylase, and these bind-
ing events activate and repress ORF50-activated viral tran-
scription, respectively (10). By sequestering CBP and thus pre-
venting its interaction with the tumor suppressor p53, ORF50
represses the transcriptional activation function of p53 and
p53-induced apoptosis (11).
STATs are a family of latent cytoplasmic proteins that are
activated by various cytokines and growth factors (12–16).
STATs have an amino-terminal protein/protein interaction do-
main, a DNA interaction domain, an SH2 domain, and a single
tyrosine phosphorylation site. Phosphorylation of this tyrosine
residue stabilizes the association of two STAT monomers
through the interaction between the phosphotyrosine and SH2
domain (12–16). These activated STAT dimers translocate into
the nucleus, where they bind to their cognate DNA response
elements. In addition to their normal roles in cell signaling, a
relationship between the activation of STATs and oncogenesis
has been shown (15, 16). A number of oncoproteins can activate
specific STATs, and the activated STAT protein participates in
oncogenesis by stimulating cell proliferation and preventing
apoptosis. Several tumor viruses are known to be associated
with STAT activation. STAT3 and STAT5 are constitutively
activated in human T cell lymphotrophic virus I-transformed T
cells (17). The herpesvirus saimiri tyrosine kinase-interacting
protein Tip-484 also activates STAT3 through up-regulation of
p56lck, a non-receptor tyrosine kinase (18). Constitutively acti-
vated STATs are also found in lymphoid and myeloid leukemia
cells and in EBV-related lymphoma cell lines (19, 20). Taken
together, these observations indicate that certain viruses mod-
ify STAT activity (particularly STAT3) to increase the persist-
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ence, replication, or oncogenic potential of the viruses. In this
report, we show that KSHV ORF50 activates STAT3-mediated
transcription without mediating tyrosine phosphorylation.
EXPERIMENTAL PROCEDURES
Plasmids—The expression plasmid that contains FLAG-tagged
STAT3 and the reporter plasmid p3XLy6e-luc were kind gifts from Dr.
James E. Darnell. The vector pBabe-v-Src and reporter plasmids ptk-
luc and pSIE-luc were gifts from Dr. Richard Jove. ORF50 and the
ORF50 deletion mutants were subcloned into pcDNA3 (EcoRI and XhoI
sites) (Invitrogen, Carlsbad, CA) using PCR. Green fluorescent protein
(GFP) fusion vectors were constructed using pEGFP-C1 (CLONTECH,
Palo Alto, CA). The ORF50 and STAT3 fragments were introduced into
pGEX4T-1 (Amersham Biosciences, Inc., Uppsala, Sweden), and the
glutathione S-transferase (GST) fusion proteins were expressed and
purified according to the manufacturer’s instructions.
Transient Transfection Assays—Transfection assays were performed
in 293T cells using the calcium phosphate method. Transfection assays
in NIH3T3 cells were performed using LipofectAMINE Plus reagent
(Invitrogen). In all assays, the luciferase activity derived from the
reporter plasmids was determined after normalizing to the -galacto-
sidase activity from a cotransfected pRSV-gal control plasmid. All
experiments were performed in triplicate. Equivalent expression of
each plasmid was verified by Western blot assays (data not shown).
293T cells were transfected with 1 g of reporter plasmid, either 20 ng
(in 293T cells) or 1 g (in NIH3T3 cells) of pRSV-gal control plasmid,
and the amounts of the expression plasmids indicated in the figure
legends. The total amount of each expression vector was kept constant
by adding empty pCMV expression plasmid. BJAB cells were trans-
fected by electroporation as described previously (8).
GST Pull-down Assays—ORF50, STAT3, and their deletion mutants
were in vitro transcribed and translated using a T7-coupled transcrip-
tion/translation system (Promega Corp., Madison, WI). The labeled
proteins were incubated with 1 g of a GST fusion protein in binding
buffer (20 mM HEPES (pH 7.4), 100 mM NaCl, and 0.5% Nonidet P-40
supplemented with protease inhibitors). Glutathione beads were then
added, and the reaction mixture was incubated at 4 °C overnight. The
beads were washed four times with binding buffer; SDS-PAGE sample
buffer was added; and the proteins were analyzed by SDS-PAGE and
visualized by autoradiography or phosphorimaging (BAS-1500, Fuji
Film Co., Tokyo, Japan).
In Vivo Co-immunoprecipitation—293T cells were transfected with 7
g of each expression plasmid using the calcium phosphate method.
The cells were harvested 48 h after transfection and lysed in the
binding buffer (containing 1% Triton X-100) used in the GST pull-down
assays. The cell lysates were rotated in the buffer for 1 h at 4 °C before
the cell debris was removed by centrifugation. The appropriate lysates
were immunoprecipitated with the addition of antibody to GFP, hemag-
glutinin (HA), or FLAG (Sigma) and protein G resin (Santa Cruz Bio-
technology, Santa Cruz, CA). The beads were washed four times, and
the proteins were analyzed by SDS-PAGE, transferred to a nitrocellu-
lose membrane, and visualized with ECL reagent (Amersham Bio-
sciences, Inc.) according to the manufacturer’s instructions.
Immunofluorescence—GFP/ORF50 (1 g) and expression vectors
containing FLAG-tagged STAT3 were transfected into 293T cells (1 g).
Cells were fixed and immunostained 48 h after transfection. FLAG-
tagged STAT3 was detected using a rhodamine-conjugated secondary
antibody.
RESULTS
KSHV ORF50 Increases the Transcriptional Activity of
STAT-regulated Promoters—To assess whether ORF50 modi-
fies the STAT pathway, we tested the effect of ORF50 on the
expression of STAT-regulated reporter plasmids. The pSIE-luc
reporter plasmid (high affinity mutant of the c-Fos SIS-induc-
ible element, mutant m67) and the p3XLy6e-luc reporter plas-
mid (containing three copies of STAT-responsive elements
(TTCCTGTAA) in the promoter of the murine surface antigen)
are generally used as reporter plasmids for determining the
activity of STAT family proteins (21–23). The ptk-luc reporter
plasmid, which contains the herpes simplex virus thymidine
kinase promoter, was used as a negative control. KSHV ORF50
stimulated pSIE-luc expression by 45- and 58-fold in 293T cells
that had been transfected with 0.5 and 1 g of an ORF50
expression plasmid, respectively. ORF50 also activated the
ptk-luc reporter, but only by 5-fold (Fig. 1A). We then meas-
ured the effect of ORF50 on the p3XLy6e-luc reporter. Cotrans-
fection of p3XLy6e-luc and an ORF50 expression plasmid re-
sulted in a 1300-fold activation of luciferase activity (Fig. 1B).
To determine the domains of ORF50 necessary for STAT
activation, we tested the transcriptional activation function of
ORF50 deletion mutants whose functions have been described
(10). The C301–691 mutant, which has the carboxyl-terminal
half of ORF50, is unable to bind CBP and form an ORF50
homodimer (8, 10). However, the C301–691 mutant lost its
ability to stimulate the STAT-regulated promoters in 293T
cells (Fig. 1B). The N626 mutant (containing amino acids
1–626 of ORF50), which binds to CBP and can form a ho-
modimer, was still able to stimulate the above STAT-regulated
reporter plasmids in 293T cells, but to a lower degree (300-
fold). The N599 and N589 mutants were unable to stimulate
the p3XLy6e-luc reporter in 293T cells. The LXXAA mutant,
which has mutations in the CBP-binding motif, is unable to
bind CBP and is also unable to repress p53-induced transcrip-
tion and apoptosis (10, 11). However, this mutant retained its
ability to activate p3XLy6e-luc in 293T cells. We can assume
that the CBP-binding domain (LXXLL motif) in the carboxyl
terminus is not involved in the activation of the STAT-related
promoters. From these results, we conclude that (i) the carbox-
yl-terminal transcriptional activation domain is necessary for
the activation of STATs and (ii) the amino-terminal domain
FIG. 1. KSHV ORF50 activates the transcription of STAT-reg-
ulated promoters. A, 293T cells were transiently cotransfected with a
reporter gene construct (ptk-luc or pSIE-luc) and increasing amounts of
ORF50-containing expression vectors (pcDNA3/ORF50; 0 (), 0.5 (),
and 1 () g). The luciferase activity of the reporter gene in the
absence of the other expression vectors was normalized to a value of 1.
B, the effects of KSHV ORF50 (0.5 and 1 g) and its deletion mutants
(1 g each) on the transcriptional activation function of STAT were
determined by measuring the luciferase activity of the p3XLy6e-luc
reporter gene. C, to confirm the STAT promoter activation function of
ORF50, luciferase activity in the presence of ORF50 was also deter-
mined in a B cell lymphoma cell line (BJAB) and in NIH3T3 cells. We
transfected NIH3T3 cells with 1 g of the reporter gene and 0.5 () or
1 () g of ORF50 expression vectors. BJAB cells were cotransfected
with 5 g of the reporter gene and 5 () or 10 () g of ORF50. D, the
effects of IL-6 and v-Src on the transactivation of STAT3 by ORF50
were determined in 293T cells using the p3XLy6e-luc reporter. Mock,
mock transfected.
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necessary for ORF50 homodimerization and CBP binding is
also important for this stimulating function.
To test whether ORF50 can activate STATs in other cell
lines, we measured the activation of ptk-luc and p3XLy6e-luc in
mouse fibroblast NIH3T3 cells and B cell lymphoma BJAB
cells. In the presence of the ORF50 gene, the transcriptional
activity of p3XLy6e-luc increased in a dose-dependent manner,
whereas the activity of ptk-luc did not change (Fig. 1C). The
STAT-regulated promoters used in our experiments are known
to be responsive to almost all STATs, but we narrowed our
scope of research to STAT3 because it is the STAT protein most
closely related to proliferation and apoptosis. When we either
treated cells with interleukin 6 (IL-6) or transfected them with
v-Src expression plasmids (two well characterized activators of
the STAT3 pathway), ORF50 activation of p3XLy6e-luc expres-
sion was increased by 2.2- and 2-fold, respectively (Fig. 1D). As
a control, cells were either treated with IL-6 or transfected with
v-Src expression vectors in the absence of STAT3 and ORF50.
p3XLy6e-luc reporter gene expression was not much increased
by IL-6 or v-Src. When cells transfected with STAT3 expression
vectors were either treated with IL-6 or co-transfected with
v-Src expression vectors, expression of the p3XLy6e-luc re-
porter was increased by 19- and 11-fold, respectively. The stim-
ulating activity of ORF50 was reduced to one-third when cells
were cotransfected with STAT3Y (Fig. 1D), a dominant-nega-
tive mutant form of STAT3 that cannot be phosphorylated at
tyrosine 705 and that cannot be homodimerized upon stimula-
tion (22). Cotransfection of STAT3 and ORF50 stimulated the
luciferase activity by 1.5–1.8-fold compared with ORF50 alone.
The stimulating activity was also reduced to one-third with
STAT3Y. In contrast to IL-6, interferon-, which activates the
STAT1-related pathway, did not affect the stimulating activity
of ORF50 (data not shown). These data suggest a relationship
between ORF50 and STAT3 function, although we cannot ex-
clude the possibility that ORF50 modifies the STAT-regulated
reporters through interaction with other STAT family
pathways.
ORF50 and STAT3 Associate in Vivo, and This Interaction
Induces Dimerization and Nuclear Localization of STAT3—We
next sought to determine whether ORF50 modifies the tran-
scriptional activity of STAT3 by stimulating phosphorylation of
STAT3. A FLAG-tagged STAT3 expression vector and either an
ORF50 or v-Src expression vector were cotransfected into 293T
cells. Whole cell extracts of the transfected cells were precipi-
tated with anti-FLAG antibody, and the precipitates were an-
alyzed by Western blotting with antibody to the phosphoty-
rosine residue within STAT3. v-Src did stimulate the tyrosine
phosphorylation of STAT3, whereas ORF50 did not (Fig. 2A).
When STAT3 is tyrosine-phosphorylated and dimerizes, it acts
as a transcriptional activator; thus, it is possible that ORF50
associates directly with STAT3 to modify its transcriptional
activity. To test this hypothesis, we cotransfected 293T cells
with a FLAG-tagged STAT3 expression vector and a vector that
expresses either GFP alone or GFP/ORF50. Whole cell extracts
were then precipitated with either anti-FLAG or anti-GFP
antibody and analyzed by Western blotting (Fig. 2B). Compa-
rable amounts of STAT3 were precipitated with anti-FLAG
antibody from both types of cell extracts. When the membrane
that had been probed with anti-FLAG antibody was stripped
and reprobed with anti-GFP antibody, GFP/ORF50 was de-
tected, whereas the GFP protein was not detected in the pre-
cipitates. Thus, we conclude that ORF50 binds to STAT3 in
vivo.
We next determined the subcellular localization of these two
proteins in our system. Because STAT3 exits as a latently
cytoplasmic protein and ORF50 is known to be located in the
nucleus (10), we used confocal microscopy to determine the
localization of STAT3 in the absence or presence of ORF50 in
cotransfected 293T cells similar to those used for Fig. 2B. GFP
was dispersed in both the cytoplasm and nucleus in the trans-
fected 293T cells (Fig. 3A). STAT3 was dispersed mostly in the
cytoplasm, in accordance with previous observations (13–16).
When these two images were superimposed, STAT3 and GFP
did not show any relationship with respect to their location (i.e.
they did not show any yellow color, which is indicative of
co-localization in our system). GFP/ORF50 was located in the
nucleus; and, interestingly, most of the STAT3 protein was also
located in the nucleus in the presence of GFP/ORF50 even
without IL-6 or cotransfection of v-Src expression vectors. To
investigate further the co-localization of STAT3 and ORF50, we
fractionated extracts from the transfected cells into cytoplas-
mic and nuclear fractions, and each fraction was analyzed by
Western blotting (Fig. 3B). In the absence of GFP/ORF50,
STAT3 was localized chiefly in the cytoplasmic fraction. In
contrast, nearly 50% of the cellular STAT3 protein was local-
ized in the nucleus in the presence of GFP/ORF50. The amount
of nuclear STAT3 in the presence of ORF50 was comparable to
that observed in cells transfected with v-Src. These results
suggest that ORF50 recruits STAT3 to the nucleus in the
absence of any other signal, and this observation is consistent
with the fact that ORF50 stimulates STAT-regulated promot-
ers without any other stimulator of the STAT pathway.
We next determined the effect of ORF50 on the dimerization
of STAT3. ORF50 stimulated the transcriptional activity of
STAT3 without affecting the phosphorylation of STAT3. How-
ever, STAT3 must be dimerized to bind to its specific DNA
elements and thus to be an active transcriptional regulator.
Furthermore, in most cases, STAT3 translocates into the nu-
cleus after it forms a dimer. We cotransfected 293T cells with
vectors expressing HA- and FLAG-tagged STAT3 and expres-
sion vectors for either ORF50 or the N589 mutant, which lost
the activity to activate STAT-regulated promoters. The
FIG. 2. ORF50 and STAT3 associate in vivo. A, ORF50 does not
stimulate the phosphorylation of STAT3. Extracts from cells trans-
fected with ORF50 or v-Src were precipitated with anti-FLAG antibody
(-Flag) and Western-blotted with anti-FLAG antibody. The blots were
stripped and reprobed with an antibody that recognizes the phospho-
tyrosine residue in STAT3 (-PY Stat3). B, 293T cells were transfected
with the FLAG-tagged STAT3 expression vector and either a blank
vector (GFP) or an expression vector carrying GFP/ORF50. Proteins in
the cell lysates were precipitated with either anti-FLAG or anti-GFP
(-GFP) antibody, subjected to SDS-PAGE, transferred to a nitrocellu-
lose membrane, and visualized with either anti-FLAG or anti-GFP
antibody. Mock, mock transfected.
KSHV ORF50 Stimulates the Transcriptional Activity of STAT36440
amounts of FLAG- and HA-tagged STAT3 in the extracts from
the transfected cells were shown to be similar (Fig. 4A, left and
right panels). However, in the presence of ORF50, the amount
of HA-tagged STAT3, which was associated with FLAG-tagged
STAT3, was increased in a dose-dependent manner. N589 had
no effect on the dimerization of STAT3 (Fig. 4A, middle panel).
To investigate further the effect of ORF50 on STAT3 dimeriza-
tion, we conducted similar experiments in vitro. Extracts from
cells transfected with either HA- or FLAG-tagged STAT3 were
added to a purified preparation of ORF50 protein and immu-
noprecipitated with anti-FLAG antibody. ORF50 simulated the
association of the STAT3 proteins (Fig. 4B). When the anti-
FLAG precipitates were analyzed by Western blotting, we
found that the bound fraction of HA-tagged STAT3 was
increased, and ORF50 was shown to associate with these
STAT3 dimers using anti-His antibody.
Association of ORF50 and STAT3 in Vitro and Interaction
Domains within STAT3 and ORF50—To detect ORF50 and
STAT3 interaction in vitro and to decipher the domains within
ORF50 and STAT3 that participate in this interaction, we
performed GST pull-down assays using in vitro translated
STAT3 and GST/ORF50 fusion proteins (made with various
ORF50 deletion mutants) (Fig. 5A). STAT3 bound to wild-type
ORF50 and the ORF50 mutants containing the carboxyl-termi-
nal transcriptional activation domain (C301–691, C581–691,
and C607–691). N626, the carboxyl terminus (amino acids
627–691)-truncated mutant, could interact with STAT3.
STAT3, however, did not bind to the amino terminus-contain-
ing ORF50 mutants (N599, N589, and N449). N599 and N589
also showed a reduction in the ORF50 transcriptional activa-
tion function (Fig. 1B). Taken together, these results show that
the STAT3-binding domain within ORF50 is in the carboxyl-
terminal transcriptional activation domain of ORF50 (amino
acids 607–626). We also performed GST pull-down assays us-
ing in vitro translated ORF50 and GST-fused STAT3 functional
domain fragments (Fig. 5B). ORF50 bound to multiple regions
within STAT3, including the amino-terminal domain, the
DNA-binding domain, the linker domain, and the SH2 frag-
ments, whereas it did not bind to the coiled-coil and transcrip-
tional activation domain fragments.
DISCUSSION
We have shown here that KSHV ORF50 affects the tran-
scriptional activation of STAT3 through direct interaction.
FIG. 4. ORF50 induces dimerization of STAT3. A, the dimeriza-
tion of STAT3 was induced in the presence of ORF50 in vivo. Cell
extracts from 293T cells transfected with FLAG-tagged STAT3, HA-
tagged STAT3, and either ORF50 or N589 expression vectors were
immunoprecipitated with anti-FLAG (-Flag) or anti-HA (-HA) anti-
body. These precipitates were analyzed by Western blotting. B, ORF50
induces dimerization of STAT3 in vitro. Each of the extracts transfected
with FLAG- and HA-tagged STAT3 expression vectors was added to
GST pull-down buffer in the presence of His-tagged ORF50 (purified
from insect cells infected with ORF50 recombinant baculoviruses).
These reaction mixtures were precipitated with anti-FLAG antibody
and analyzed by Western blotting. -His, anti-His antibody.
FIG. 5. In vitro interaction of ORF50 with STAT3. A, the domains
within ORF50 and the ORF50 deletion mutants are shown. ORF50
contains the basic domain, the leucine zipper motif (LZ), and the tran-
scriptional activation domain (TAD). The LXXLL motif, which interacts
with CBP, is located from amino acids 593 to 597 of ORF50. The
GST-fused ORF50 fragments were purified and used in GST pull-down
assays performed with glutathione-Sepharose beads. STAT3 was trans-
lated in vitro and labeled with [35S]methionine. B, the domains of
STAT3 are indicated. STAT3 contains the DNA-binding domain, the
SH2 domain, and the carboxyl-terminal transcriptional activation do-
main. The GST-fused STAT3 fragments and in vitro translated ORF50
were used in GST pull-down assays.
FIG. 3. ORF50 co-localizes with STAT3 and induces nuclear
re-localization of STAT3. A, GFP/ORF50 (1 g) and the FLAG-tagged
STAT3 expression vector (1 g) were transfected into 293T cells. Cells
were fixed and immunostained 48 h after transfection. FLAG-tagged
STAT3 was detected using a rhodamine-conjugated secondary antibody
against anti-FLAG monoclonal antibody. B, cytoplasmic and nuclear
extracts from 293T cells transfected with the FLAG-tagged STAT3
expression vector and either GFP/ORF50 or a v-Src expression vector
were analyzed by Western blotting. Mock, mock transfected; -Flag,
anti-FLAG antibody.
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With respect to viral physiology, this observation is not sur-
prising because many viral proteins such as EBV, human T cell
lymphotrophic virus I, and herpesvirus saimiri modulate
STAT-related activity to enhance viral replication. The ability
of these viruses to stimulate STATs is closely related to viral
oncogenic potential (17–20). In this report, we focused on the
ability of ORF50 to induce STAT3 activity, but it is possible
that ORF50 also associates with other STAT family proteins
and can affect their function.
ORF50 interacts with multiple regions within STAT3 (Fig. 5,
A and B). The amino-terminal domain in STAT3 is a protein/
protein interaction domain, and this domain interacts with
other dimeric forms of STAT and CBP (12–16). The STAT3
DNA-binding domain interacts with a cellular transcriptional
factor (c-Jun) to augment the transcriptional activity of STAT
(24, 25). The SH2 domain interacts with a phosphotyrosine
residue of another STAT monomer to form the activated di-
meric form of STAT proteins (12–16). It is possible that ORF50
modulates these diverse protein/protein interactions, and an
example of this is shown herein. The crystal structure of the
dimeric STAT1 proteins (coiled-coil, DNA-binding, linker, and
SH2 domains) has been published (26). According to the data,
the coiled-coil domains project outward from the C-shaped core
(DNA-binding, linker, and SH2 domains) around DNA, and the
three domains in the core region are in close proximity to each
other. This core region is also located in proximity to the other
core region in the dimeric structure. So, it seems to be quite
logical that ORF50 interacts only with the DNA-binding,
linker, and SH2 domains, but not with the coiled-coil domain. It
is possible that ORF50 could stabilize the dimeric form of STAT
protein through the interaction between the core region of
STAT and ORF50. ORF50 induced STAT3 dimerization in vivo
and in vitro without tyrosine phosphorylation of STAT3. This
ORF50-induced dimerization of STAT3 seems to be related to
the STAT3-stimulating activity of ORF50 because the carboxyl
terminus- deleted mutant N589, which completely lost its stim-
ulating activity, also lost its ability to induce STAT3 dimeriza-
tion. Fig. 6 shows the possible mechanism of ORF50-induced
STAT3 activation. A STAT3 monomer is activated with v-Src or
IL-6 to form a dimer, translocates into the nucleus, and inter-
acts with the specific DNA elements (12–16). ORF50 recruited
STAT3 to the nucleus and induced the dimerization of STAT3
without any additional signal. When cells do encounter other
signals such as v-Src and IL-6, a large proportion of STAT3
molecules are located in the nucleus, and this may increase the
probability that ORF50 will meet a STAT3 protein. Another
possible mechanism of ORF50-induced translocation of STAT3
is that ORF50 could inhibit the interaction of CRM1 and
STAT3 because ORF50 and CRM1 both interact with STAT3 at
its DNA-binding domain. CRM1 is involved in the nuclear
export of STAT proteins and serves to inactivate the STAT
pathway (27). It is possible that ORF50 could inhibit the
STAT3/CRM1 interaction and induce the retention of STAT3 in
the nucleus.
KSHV ORF50 is a viral transcriptional factor that activates
transcription of many viral genes to induce the lytic phase of
KSHV. ORF50 modifies the activity of cellular transcription
factors such as p53 through association with CBP (10, 11). In
addition, the expression of ORF50 is closely associated with the
development of KSHV-related diseases (9). We have shown
here that ORF50 also has a role in the modulation of cell
growth. KSHV vIL-6 has been shown to have transforming
activity through activation of the STAT pathway and to be
mostly expressed in the lytic phase (28–32). We showed here
that STAT3 stimulation of ORF50 cooperates with v-Src and
human IL-6. Therefore, it is possible that ORF50 and vIL-6
cooperate to stimulate the STAT pathway.
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